GM1 Gangliosidosis Market Report 2026

GM1 Gangliosidosis Market Overview

• GM1 Gangliosidosis market size has reached to $0.57 billion in 2025 • Expected to grow to $0.96 billion in 2030 at a compound annual growth rate (CAGR) of 10.8% • Growth Driver: Rising Adoption Of Gene Therapy Fuels Growth In Rare Disease Treatments • Market Trend: Strategic Partnership To Advance Gene Therapies For Rare Diseases • North America was the largest region in 2025.

What Is Covered Under GM1 Gangliosidosis Market?

GM1 gangliosidosis is a rare, inherited neurodegenerative disorder caused by a deficiency of the β-galactosidase (GLB1) enzyme, leading to toxic accumulation of GM1 gangliosides in the brain and other tissues. It results in progressive neurological decline, developmental delays, muscle weakness, and organ enlargement. The main disease types in GM1 gangliosidosis are type 1 GM1 gangliosidosis, type 2 GMT gangliosidosis, and type 3 GMT gangliosidosis. Type 1 GM1 gangliosidosis is the most severe form, diagnosed in infancy, characterized by rapid neurological degeneration. Affected children experience progressive motor and cognitive decline, resulting in early death. Treatment options include anticonvulsants, bone marrow transplantation, cord-blood hematopoietic stem cell transplantation, enzyme replacement therapy, and gene therapy. These are utilized in research institutes, hospitals, and others.

What Is The GM1 Gangliosidosis Market Growth Forecast?

The gm1 gangliosidosis market size is expected to see rapid growth in the next few years. It will grow to $0.96 billion in 2030 at a compound annual growth rate (CAGR) of 10.8%. The growth in the forecast period can be attributed to gene therapy pipeline growth, orphan drug incentives, improved diagnostic screening, increased patient advocacy, biotechnology funding expansion. Major trends in the forecast period include rising focus on rare disease drug development, increased research in gene therapy, growing use of enzyme replacement therapies, expansion of newborn genetic screening, increased clinical trial activity.

What Is The Driver Of The GM1 Gangliosidosis Market?

The increasing adoption of gene therapy is expected to fuel the growth of the GM1 gangliosidosis market going forward. Gene therapy is a medical treatment that involves altering or replacing genes within a person's cells to treat or prevent disease. The increasing adoption of gene therapy is driven by advancements in genetic research, improved treatment outcomes for previously untreatable conditions, and growing regulatory support for innovative therapies. Gene therapy for GM1 gangliosidosis involves delivering a functional copy of the defective gene (GLB1) to patient cells to restore β-galactosidase enzyme activity and reduce toxic substrate buildup. For instance, in January 2024, according to the American Society of Gene & Cell Therapy, a US-based organization for gene and cell therapy, In Q4 2023, the number of gene therapies in Phase III rose by 10% compared to the previous quarter, representing the first increase since Q3 2022. Therefore, the increasing adoption of gene therapy is driving the growth of the GM1 gangliosidosis industry.

Key Players In The Global GM1 Gangliosidosis Market

Major companies operating in the gm1 gangliosidosis market are Pfizer Inc, Sanofi S A, Novartis AG, Takeda Pharmaceutical Company Limited, Sarepta Therapeutics Inc, CRISPR Therapeutics AG, REGENXBIO Inc, Passage Bio Inc, Orchard Therapeutics plc, AVROBIO Inc, uniQure N V, Lysogene S A, Sio Gene Therapies Inc, bluebird bio Inc, Axovant Gene Therapies Ltd, Lysosomal Therapeutics Inc, Encoded Therapeutics Inc, Abeona Therapeutics Inc, JCR Pharmaceuticals Co Ltd, Sangamo Therapeutics Inc

Global GM1 Gangliosidosis Market Trends and Insights

Major companies operating in the GM1 gangliosidosis market are focusing on strategic partnerships to sustain their position in the market. Strategic partnerships play a crucial role in advancing gene therapy development by combining expertise, resources, and technologies to accelerate research, clinical trials, and commercialization. For instance, in October 2024, GEMMA Biotherapeutics Inc., a US-based biotechnology company, partnered with Oswaldo Cruz Foundation (Fiocruz), a Brazil-based health research institution, to develop gene therapies for rare diseases, including GM1 gangliosidosis. The agreement involves up to $100 million in funding from Fiocruz for clinical research and manufacturing, aimed at making these advanced therapies accessible through Brazil's public healthcare system. This collaboration emphasizes technology transfer and aims to democratize access to treatments that were previously limited to higher-income populations.

What Are Latest Mergers And Acquisitions In The GM1 Gangliosidosis Market?

In August 2024, Passage Bio Inc., a US-based biotech company, partnered with GEMMA Biotherapeutics, to advance pediatric gene therapies. As part of this collaboration, Passage Bio is out-licensing three pediatric gene therapies targeting lysosomal storage diseases including PBGM01 for GM1 gangliosidosis, PBKR03 for Krabbe disease, and PBML04 for metachromatic leukodystrophy. GEMMA Biotherapeutics Inc. is a US-based biotechnology research company that specializes in developing and commercializing genetic medicines for rare pediatric diseases.

What Defines the GM1 Gangliosidosis Market?

The GM1 gangliosidosis market consists of revenues earned by entities by providing services such as gene therapy, diagnostic testing, patient care, and clinical trials. The market value includes the value of related goods sold by the service provider or included within the service offering. The GM1 gangliosidosis market also includes sales of diagnostic tools, research kits, biomarkers, and assistive devices. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the GM1 Gangliosidosis Market Report 2026?

The gm1 gangliosidosis market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the gm1 gangliosidosis industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.